Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
about
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyRole of receptor tyrosine kinases and their ligands in glioblastoma.Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutantsHigh incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug ResistanceUrothelial carcinomas: a focus on human epidermal receptors signalingDual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm.KRAS mutant colorectal tumors: past and presentEffect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialEGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem CellsWnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsMET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infectionEpidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer.Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.Advances in Targeting HER3 as an Anticancer TherapyA common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.Tackling the cancer signal transduction “labyrinth”: a combinatorial use of biochemical tools with mathematical models will enhance the identification of optimal targets for each molecular defect.Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.
P2860
Q26849503-F4A0F437-1551-490A-BBD1-11B666169D06Q33883849-C02ED909-F86A-45C1-BBAF-ADE730CFC1EAQ33932286-6B7194FD-ED4E-491D-A59A-71A04EB0315CQ33937876-B4B8DEF1-E620-41F9-828F-8C58DCFD1A39Q34128962-7FC2F123-90CA-4A20-AD15-5457FD531053Q34221586-E308B405-520C-41A7-B525-9DF81C8F09D0Q34273411-482CB01A-23F1-42AB-8F4A-EA8AEDC19C6CQ34533693-2645948D-EFBE-4DE7-B754-F6719AD45173Q35143027-E9DF2413-C0C8-49D6-AC79-F294A1FBCC3FQ35172558-6D961818-F22A-4C3B-B8B3-87E5936C8CFDQ35625440-673FAC6E-BFC7-451A-8B9C-CAD90EBB18ADQ35876828-42A9A027-952E-4CCB-B91D-A4949C2265B7Q36100844-FBC3B207-F24E-404D-8530-66FD42BA8601Q36233987-5A0B61F7-52E8-47D0-B452-10DB8E0CC97EQ36310662-32F39DE4-F8CF-4245-B23A-B04907AF197CQ36544112-F0351607-CB04-425D-BA14-BBAF1EE69AC3Q36740744-E1444C6F-3283-4315-AFEE-DB7AD5116B34Q37735662-253493B9-EFE7-4D98-983E-A4C46652E89FQ38161361-6E2AD820-4048-4734-97E2-265C8F91C30FQ38748906-DA878460-C5B3-4A30-B706-6EDE4456301BQ38778872-8A8103DD-B46B-46C2-8313-B71C6BEDBA51Q38844694-20BF5D5B-BA4A-4943-89D3-1941B96FDE9AQ38904799-F61EF73A-352D-4D36-B542-C18332F3C03DQ39025928-B7E1070F-0E6A-4F53-942C-949234556F8BQ39133025-857CCC35-7C20-4786-9BDE-CC35C241135BQ39214964-564D5AB9-F3B4-4139-8621-54DC29C479E6Q39287960-9F7B8F59-30C3-4A1E-AFED-EABFD997E33FQ39404792-6CF55F7B-E30F-4566-8F0F-575578FC4731Q41621146-F9D30E53-AAC9-418E-9A30-F1B871C532A2Q41905212-AF1DC836-A25D-4AA1-8070-6E9F6ED82E5BQ43805357-8A2437DF-89A1-4F51-8DE1-5F6C42003D58Q43902936-1495BD12-0F65-408F-A88A-82A1029052D6Q48806131-69639805-7930-44D6-AF93-7E85B46DEBF8Q50882714-888B2999-0128-48D9-B92F-91C315593D6BQ51145627-66142946-47BA-4914-B03B-961C3D355BD9Q52657095-EC0E7395-59F1-40DD-8D9F-103349219473Q53688956-78761A0A-0F59-4961-9B8C-BBD6BA5F0524Q54979642-D64C99F0-C20B-49B7-8CE4-B78BC4E1BF40Q55031644-63BC4593-5C6C-4A8F-80A4-014AA2CC3CDC
P2860
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@en
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@nl
type
label
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@en
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@nl
prefLabel
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@en
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@nl
P2093
P1433
P1476
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
@en
P2093
Athanasios G Papavassiliou
Michalis V Karamouzis
Panagiotis A Konstantinopoulos
P304
P356
10.1016/S1470-2045(09)70137-8
P577
2009-07-01T00:00:00Z